Korean biosimilars are penetrating deep into the European market. Sales of multinational pharmaceutical companies' original drugs fell sharply because of these biosimilars.
According to the pharmaceutical industry on April 18, multinational pharmaceutical company Roche reported that European sales of Herceptin (ingredient name Trastuzumab) in the first quarter of this year recorded 300 million francs (340 billion won), down 44 percent from the same period last year.
Samsung Bioepis and Celltrion launched Herceptin biosimilars Ontruzant and Herzuma, respectively, in Europe last year. According to pharmaceutical market research firm IQVIA’s data, Celltrion's Herzuma occupied 10 percent of the Trastuzumab market in Europe in the fourth quarter of last year, a record achieved in six months after its launch.
Celltrion Healthcare, which conducts overseas sales, distribution and marketing of Celltrion biosimilars, said Herzuma has the largest market share of Herceptin biosimilars launched in Europe.
European sales of Roche’s another biopharmaceutical product Rituxan (product name: Mapthera, ingredient name: rituximab) also fell 38 percent in the first quarter of this year.
A bio-industry official said, "Sales of domestic biosimilars, which are comparable in efficacy but lower in price than original drugs, are increasing to the extent of threatening the original drugs in the European market."